The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders
Abstract
OBJECTIVE: To compile and evaluate all available data suggesting an association between selective serotonin-reuptake inhibitor (SSRI) administration and the occurrence of movement disorders, and to characterize these reactions in terms of onset, duration, treatment and outcome, and potential predisposing factors. METHODOLOGY: Reports of movement disorders were identified by conducting a comprehensive literature search that included tertiary adverse drug reaction resources, MEDLINE, EmBASE, Biological Abstracts, Current Contents, Reactions, ClinAlert, and International Pharmaceutical Abstracts. In addition, reports were solicited from the Canadian proprietary manufacturers of SSRIs, and from the Therapeutic Products Program of Health Canada. Each case was then classified according to the description of the movement disorder, based on predefined diagnostic criteria. RESULTS: A total of 127 published reports of SSRI-induced movement disorders were identified involving akathisia (n = 30), dystonia (19), dyskinesia (12), tardive dyskinesia (6), parkinsonism (25), and 15 cases of mixed disorders. Ten isolated cases of bruxism were identified. Ten additional reports could not be classified. Manufacturers of SSRIs provided 49 reports of akathisia, 44 of dystonia, 208 of dyskinesia, 76 of tardive dyskinesia, 516 of parkinsonism, and 60 of bruxism. Treatment strategies included discontinuation of the SSRI; dosage reduction; or the addition of a benzodiazepine, β-blocker, or anticholinergic agent. CONCLUSIONS: SSRI use appears to be associated with the development of movement disorders, as either a direct result of the drug or exacerbation of an underlying condition. Predisposing factors may include the use of neuroleptics, existing neurologic diagnoses, or preexisting movement disorders. Clinicians should be cognizant of the potential for these reactions, as prompt recognition and management is essential in preventing potentially significant patient morbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Pharmacotherapy: A Pathophysiologic Approach
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-5-447_3 · Cited by 2,407
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C., & Long, G. W. (1991) · JAMA · doi:10.1001/jama.1991.03460200114048 · Cited by 1,060
Drugs and the treatment of psychiatric disorders
Baldessarini, R. J. (1996) · Medical Entomology and Zoology · Cited by 683
Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors
Leo, R. J. (1996) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v57n1002 · Cited by 364
Binding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B., Nelson, A., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349
Fluoxetine-induced akathisia: clinical and theoretical implications.
Lipinski, J. F., Mallya, G. K., Zimmerman, P., & Pope, H. G. (1989) · PubMed · Cited by 279
SSRI-associated nocturnal bruxism in four patients.
Ellison, J. M., & Stanziani, P. J. (1993) · PubMed · Cited by 167
Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant
Meltzer, H. Y., Young, M., Metz, J., Fang, V. S., Schyve, P. M., & Arora, R. C. (1979) · Journal of Neural Transmission · doi:10.1007/bf01250091 · Cited by 167
Fluoxetine and extrapyramidal side effects
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.122 · Cited by 158
Increase of Parkinson disability after fluoxetine medication
Steur, E. N. H. J. (1993) · Neurology · doi:10.1212/wnl.43.1_part_1.211 · Cited by 155
Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia.
Rothschild, A. J., & Locke, C. (1991) · PubMed · Cited by 144
Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine
Tate, J. L. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.3.399b · Cited by 114
Fluoxetine and extrapyramidal side effects
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.10.1352a · Cited by 99
Does fluoxetine exacerbate Parkinson's disease?
Caley, C. F., & Friedman, J. H. (1992) · PubMed · Cited by 90
Fluoxetine, Fluvoxamine and Extrapyramidal Tract Disorders
Baldwin, D. S., Fineberg, N. A., & Montgomery, S. (1991) · International Clinical Psychopharmacology · doi:10.1097/00004850-199100610-00007 · Cited by 87
Adler, L. A., & ANGRIST, B. M. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00158-y · Cited by 49
A case of Parkinson's disease exacerbated by fluoxetine
Chouinard, G., & Sultan, S. (1992) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470070109 · Cited by 48
Complex movement disorders induced by fluoxetine
Bharucha, K. J., & Sethi, K. D. (1996) · Movement Disorders · doi:10.1002/mds.870110318 · Cited by 47
LaPorta, L. D. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199306000-00013 · Cited by 41
Persistent dyskinesia in a patient receiving fluoxetine
Budman, C. L., & BRUUN, R. D. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1403a · Cited by 41
Mander, A. G., McCausland, M., Workman, B., Flamer, H. E., & Christophidis, N. (1994) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048679409075647 · Cited by 37
Extrapyramidal symptoms in a patient treated with fluvoxamine.
Wils, V. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.4.330 · Cited by 35
Dystonias and dyskinesias of the jaw associated with the use of SSRIs
Fitzgerald, K., & Healy, D. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100308 · Cited by 35
Parkinsonism Associated with Fluoxetine and Cimetidine: A Case Report
Leo, R. J., Lichter, D. G., & Hershey, L. A. (1995) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879500800406 · Cited by 34
Tardive dyskinesia in a patient taking haloperidol and fluoxetine
Stein, M. H. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.683a · Cited by 33
Fluoxetine-associated dystonia
Dave, M. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.1.149a · Cited by 31
Poyurovsky, M., Meerovich, I., & Weizman, A. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199506000-00008 · Cited by 28
Potential Withdrawal Syndrome Associated with Ssri Discontinuation
Lazowick, A. L., & Levin, G. M. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502901215 · Cited by 28
Fluoxetine and parkinsonism in patients taking carbamazepine
Hb, G., van der Woude, J., & Touw, D. J. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1604b · Cited by 26
Worsening of parkinsonism with fluvoxamine—two cases
Meco, G., Bonifati, V., Fabrizio, E., & Vanacore, N. (1994) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470090607 · Cited by 20
Chong, S. A., & Tan, C. H. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199608000-00013 · Cited by 16
Acute organic brain syndrome after fluoxetine treatment
Singh, R. K., Gupta, A. K., & Singh, B. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.295b · Cited by 11
Cited by
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
N eurobiological M echanisms I nvolved in S leep B ruxism
Lavigne, G. J., Kato, T., Kolta, A., & Sessle, B. J. (2003) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130301400104 · Cited by 497
Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression
Mace, S., & Taylor, D. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.917 · Cited by 315
Sleep Bruxism: A Comprehensive Overview for the Dental Clinician Interested in Sleep Medicine
Carra, M. C., Huynh, N., & Lavigne, G. (2012) · Dental Clinics of North America · doi:10.1016/j.cden.2012.01.003 · Cited by 306
Metadata
- Authors
- Gerber, P. E., & Lynd, L. D.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 1998-06
- Volume
- 32
- Issue
- 6
- Pages
- 692-698
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2165743028
- Cited by
- 267
- References
- 33
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.